Latest News
-
Wednesday - May 12, 2021
First quarter of 2021:
Bayer: successful start to 2021
Good operational performance – sales and earnings negatively impacted by currency of 938 million euros and 337 million euros / Group sales up by 2.8 percent (Fx & portfolio adj.) to 12.328 billion euros / EBITDA before special items down 6.2 percent to 4.118 billion euros due to currency / Strong sales growth at Crop Science (Fx & portfolio adj.) in improved market environment / Sales at Pharmaceuticals (Fx & portfolio adj.) at prior-year level / Consumer Health ahead of competition with continuous good performance / Net income advances by 40.3 percent to 2.089 billion euros / Core earnings per share decline by 3.0 percent to 2.59 euros / Outlook for 2021 confirmed » more
-
Tuesday - May 11, 2021
Not intended for U.S. and UK Media
Bayer presents expanded research and new approaches to advance cancer care at 2021 ASCO Annual Meeting
Updated long-term efficacy and safety data of larotrectinib (Vitrakvi™) for patients with TRK fusion cancer from an integrated dataset, sub-analyses for TRK fusion cancer patients with primary central nervous system (CNS) tumors and lung cancer, respectively, as well as updated results from an intra-patient comparison to be featured / In prostate cancer, a key therapeutic area for Bayer, the safety of the Targeted Alpha Therapy radium-223 dichloride (Xofigo™) in combination with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) will be highlighted with data from the ongoing PEACE-III study; additional early-stage results in different tumor types to be presented / Additional research to highlight tolerability of darolutamide (Nubeqa™) from extended follow-up in the Phase III ARAMIS trial in non-metastatic castration-resistant prostate cancer (nmCRPC) as well as data from the ODENZA trial exploring patient preferences between darolutamide and enzalutamide in men with mCRPC / Data across other disease states on Bayer’s growing oncology portfolio with copanlisib, regorafenib and sorafenib will also be presented » more
-
Monday - May 10, 2021
Not intended for U.S. and UK Media - American College of Cardiology’s 70th Annual Scientific Session (ACC.21):
Bayer announces two late-breaking presentations which include data from FIDELIO-DKD (finerenone) and VOYAGER PAD (Xarelto™) Phase III studies
New prespecified exploratory analysis from the FIDELIO-DKD study data provides insight into the efficacy of finerenone on new onset atrial fibrillation or flutter (AFF) in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) / New VOYAGER PAD study data evaluates the impact of Xarelto (rivaroxaban) plus aspirin in patients with symptomatic peripheral artery disease (PAD), post peripheral revascularization, on the reduction in risk of total (first and potentially subsequent) events / New data providing further insights into the use of vericiguat in patients with symptomatic chronic heart failure including those with coronary artery disease, a patient population known to have a poor prognosis » more
-
Monday - May 10, 2021
Not intended for U.S. and UK Media
Bayer’s finerenone meets primary endpoint in Phase III FIGARO-DKD cardiovascular outcomes study in patients with chronic kidney disease and type 2 diabetes
Finerenone significantly reduced the composite primary endpoint of cardiovascular death and non-fatal cardiovascular events versus placebo when added to standard of care / Following the FIDELIO-DKD study, FIGARO-DKD is the second positive Phase III study within the finerenone study program in chronic kidney disease (CKD) and type 2 diabetes (T2D) to meet its primary endpoint / Patients with CKD and T2D are three times more likely to die from a cardiovascular-related cause than those with type 2 diabetes alone / Based on the comprehensive finerenone clinical trial program, finerenone is the first investigational non-steroidal, selective mineralocorticoid receptor (MR) antagonist to demonstrate renal and cardiovascular benefits in patients with chronic kidney disease and type 2 diabetes » more
-
Thursday - May 6, 2021
Data management and data transfer
Climate FieldView™, CLAAS TELEMATICS offer easy data management to help simplify farming operations » more
-
Wednesday - May 5, 2021
Bayer Foundation supports scientists in sub-Saharan Africa:
Collaboration with Alexander von Humboldt Foundation expanded
Together with Alexander von Humboldt Foundation, Bayer Foundation promotes scientists in sub-Saharan Africa through fellowships and a research hub / Bayer Foundation provides a total of EUR 3 million for the six-year collaboration » more
-
Friday - April 30, 2021
Bayer and its partners, through their Better Life Farming partnership model, receives special United Nations recognition for their support to smallholder farmers
Presented by the United Nations Economic Cooperation and Integration (UNECE) PPP (Public Private Partnership) Forum, Better Life Farming is awarded its Build Back Better Infrastructure Award for Stakeholder Engagement / The honor aligns with this year’s UNECE PPP Forum’s “Build Back Better” theme recognizing innovative thinking and creative ideas advancing the UN’s Sustainable Development Goals, while rebuilding global communities post COVID / Out of 66 global submissions, Better Life Farming was among 6 projects to receive the special commendation » more
-
Tuesday - April 27, 2021
Online
Annual Stockholders' Meeting 2021 » more
-
Tuesday - April 27, 2021
CEO Werner Baumann at the Annual Stockholders’ Meeting of Bayer AG:
“We’re optimistic for the future”
Stable operational development in fiscal 2020 despite the COVID-19 pandemic / Dividend of 2.00 euros per share proposed / Early indications of a successful start to 2021 / Board of Management regards Bayer as better positioned than almost any other company to realize the long-term innovation potential of the bio-revolution / Stockholders to elect two new Supervisory Board members » more
-
Tuesday - April 20, 2021
RAGT and Bayer sign an agreement to develop hybrid wheat seeds for European markets
New partnership aims to provide farmers with new high-potential wheat varieties, enhancing sustainable agricultural practices » more
-
Wednesday - April 14, 2021
Apply now for THRIVE | Bayer sustainability challenge
Bayer and SVG Ventures | THRIVE partner to tackle agriculture’s grand challenge » more
-
Saturday - April 10, 2021
Not intended for U.S. and UK Media – Plenary Session at AACR Annual Meeting 2021:
Combination of copanlisib and rituximab significantly increases progression-free survival in patients with relapsed indolent non-Hodgkin's Lymphoma
Copanlisib is the first and only PI3K inhibitor to demonstrate broad and superior efficacy in combination with rituximab in patients with relapsed indolent non-Hodgkin’s Lymphoma (iNHL) compared to rituximab and placebo / Phase III trial CHRONOS-3 showed the combination of copanlisib and rituximab resulted in a 48% reduction in the risk of disease progression or death in patients with iNHL / The strong reduction in risk of progression or death was observed across all prespecified iNHL subtypes / The adverse event (AE) profile of the copanlisib and rituximab combination was manageable and generally consistent with previous data on copanlisib and rituximab as individual therapies / Bayer is discussing the data from CHRONOS-3 with health authorities worldwide » more
-
Tuesday - April 6, 2021
Not intended for U.S. and UK Media
Bayer to present new clinical data in indolent non-Hodgkin’s Lymphoma and additional research on its oncology portfolio at AACR Annual Meeting 2021
Oral presentation in a Clinical Trials Plenary Session on April 10 to highlight the Phase III trial CHRONOS-3 evaluating copanlisib (Aliqopa™) plus rituximab compared to rituximab and placebo in relapsed indolent non-Hodgkin’s Lymphoma (iNHL) / New data also include research into Bayer’s precision oncology treatment larotrectinib (Vitrakvi™) on long-term outcomes in patients with TRK fusion cancer and biomarker research in this patient population / Data from Bayer’s established and growing prostate cancer portfolio, including darolutamide (Nubeqa™), radium-223 dichloride (Xofigo™), and targeted thorium conjugates (TTC) from its Targeted Alpha Therapy platform will be showcased / Introduction of novel treatment approaches in the areas of precision molecular oncology and immuno-oncology » more
-
Wednesday - March 31, 2021
Industry leading digital farming platform Climate FieldView™ launches in South Africa
The Climate Corporation, Bayer’s digital agriculture arm, expands its global footprint to advance data-driven innovation for farmers around the world » more
-
Tuesday - March 23, 2021
Not intended for U.S. and UK Media
Bayer receives approval for Vitrakvi™ in Japan
Precision oncology treatment Vitrakvi™ (larotrectinib) approved for the treatment of NTRK fusion-positive advanced or recurrent solid tumors / In clinical studies, larotrectinib demonstrated high response rates and durable responses in adults and children with TRK fusion cancer, including responses and a high disease control rate in primary central nervous system (CNS) tumors / The Japanese marketing authorization of Vitrakvi follows the approval of the expanded use of FoundationOne®CDx, a comprehensive genomic profiling (CGP) test, in Japan for use as a companion diagnostic (CDx) to identify patients with TRK fusion cancer who could benefit from treatment with Vitrakvi » more
-
Friday - March 12, 2021
Bayer’s unmatched R&D investment powers industry-leading Crop Science portfolio
Commercialized ten new formulations and more than 430 new hybrids and varieties across corn, soybeans, cotton and vegetables. Three biotech trait projects advance to launch phase / Advanced eight new small molecule crop protection actives / Leading soybean pipeline to offer the greatest weed control flexibility, premium genetics » more
-
Friday - March 12, 2021
Elections at the Annual Stockholders' Meeting on April 27, 2021:
Bayer to further strengthen expertise and international profile of its Supervisory Board
Fei-Fei Li and Alberto Weisser proposed as successors to Johanna Faber and Prof. Dr. Wolfgang Plischke / Supervisory Board compensation to be adjusted » more
-
Wednesday - March 10, 2021
Capital Markets Day 2021:
Bayer expects dynamic growth with higher profitability in the coming years and is accelerating its transformation
Crop Science: Clear innovation leader in its industry – expected sales and earnings growth above market / Pharmaceuticals: Further growth planned through 2023, new products expected to largely offset the effect of patent expirations – position in cell and gene therapy to be expanded / Consumer Health: Moved from industry underperformer to outperformer – further sales and earnings improvements planned / Core earnings per share anticipated to increase to 7.00 to 7.50 euros by 2024 / Further operational improvements to raise free cash flow to 5 billion euros by 2024 / Bayer in an excellent position to benefit from the biorevolution in health and nutrition » more
-
Monday - March 1, 2021
International conference for horticulturists marks debut of Bayer’s latest crop protection product
Bayer to launch Vynyty Citrus®, its newest biological product to control citrus farm pests during virtual symposium » more
-
Thursday - February 25, 2021
Financial News Conference
Full Year 2020 Results » more
Copyright @ Bayer AG
Search
Publications
Newsletter
Events
Thursday, August 5, 2021
Half-Year Report 2020
Additional Press Events
Investor Relations Events
BayKomm Events
Download Center - Selection
Bayer TV